Postoperative Adjuvant Chemoradiotherapy ± PD ‐1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma
Cancer Reports · 2026-03 · 9 (3)
DOI: 10.1002/cnr2.70488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 27.02.2026. Verfasst von Zhiqiang Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Chemoradiotherapy, Adjuvant, Head and Neck Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: t535 Talent Project of First Affiliated Hospital of Kunming Medical University, Yunnan Fundamental Research Projects, Yunnan Fundamental Research Kunming Medical University Projects.
Abstract (Originalsprache)
Background
Postsurgical immunotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) remains elusive. This study assesses the value and significance of postoperative immunotherapy in the treatment of locally advanced HNSCC.
Methods
In total, 212 patients with locally advanced HNSCC who underwent radical surgery were stratified into three treatment groups: adjuvant radiotherapy alone, adjuvant chemoradiotherapy (CRT), and adjuvant chemoradiotherapy plus immunotherapy (PD‐1 Ab). A comprehensive analysis was conducted to assess survival outcomes and prognostic factors across diverse patient cohorts.
Results
Four patients were lost to follow‐up, with a follow‐up rate of 98.1% and a median follow‐up time of 41 months (IQR 24–68). A total of 64/212 individuals died, with cancer being the cause of 62 cases and noncancer causes accounting for the remaining two deaths; 62/212 (29.2%) patients experienced relapse and/or metastasis. The 3‐year OS rates for the radiotherapy group, CRT group, and CRT plus PD‐1 Ab group were 54.8%, 75.4%, and 82.2%, respectively. However, no statistically significant difference in OS or PFS was observed between the CRT and CRT + PD‐1 Ab groups ( p all > 0.05), although both were superior to radiotherapy alone ( p all < 0.05). Multivariate analysis indicated that age, smoking history, TNM stage and treatment method were independent prognostic factors for OS ( p all < 0.05). Smoking history and treatment methods were independent prognostic factors for PFS and DMFS ( p all < 0.05).
Conclusion
PD‐1 Ab may contribute less to tumors with better treatment outcomes from concurrent chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
- Department of 2nd Otorhinolaryngology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
- Department of 1st Otorhinolaryngology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
- Department of Oral and Maxillofacial Surgery, Kunming Medical University School and Hospital of Stomatology, Kunming, China.
- Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- Department of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, People's Republic of China.
ORCID-Profile: Zhiqiang Wang, Qingqing He, Donghui Jiang, Sheng Cheng, Jingyu Gao, Yan Wang, Shuai Fu, Qing Ying Cui, Yanli Yang, Li Lv, Yuchuan Xu, Yan Li, Rui Tian, Chunlei Ge, Rongqing Li
Förderung
- t535 Talent Project of First Affiliated Hospital of Kunming Medical University
- Yunnan Fundamental Research Projects
- Yunnan Fundamental Research Kunming Medical University Projects
- Doctoral Research Start-up Fund for First Affiliated Hospital of Kunming Medical University
- National Natural Science Foundation of China
- Yunnan Health Training Project of High Level Talents
- Precision Radiotherapy Science and Technology Innovation Team of Yunnan Universities
Zitieren
APA
Wang, Z., He, Q., Jiang, D., Cheng, S., Gao, J., Wang, Y., Fu, S., Cui, Q. Y., Yang, Y., Lv, L., Xu, Y., Li, Y., Tian, R., Ge, C., & Li, R. (2026). Postoperative Adjuvant Chemoradiotherapy ± PD ‐1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma. Cancer Reports, 9(3). https://doi.org/10.1002/cnr2.70488
Vancouver
Wang Z, He Q, Jiang D, Cheng S, Gao J, Wang Y, et al. Postoperative Adjuvant Chemoradiotherapy ± PD ‐1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma. Cancer Reports. 2026;9(3). doi:10.1002/cnr2.70488
BibTeX
@article{Wang2026,
author = {Wang, Zhiqiang and He, Qingqing and Jiang, Donghui and Cheng, Sheng and Gao, Jingyu and Wang, Yan and Fu, Shuai and Cui, Qing Ying and Yang, Yanli and Lv, Li and Xu, Yuchuan and Li, Yan and Tian, Rui and Ge, Chunlei and Li, Rongqing},
title = {Postoperative Adjuvant Chemoradiotherapy ± PD ‐1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/cnr2.70488}
}
EUVIMED